Jyong Biotech Ltd. (JYB)

Jyong Biotech was planning to go public, but the IPO was withdrawn on Dec 20, 2023.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -6.63M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About JYB

Jyong Biotech is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). Among our drug candidates, we have filed the new drug application in the US, for MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms. PCP, our key new drug candidate dev... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Country Taiwan
Stock Exchange NASDAQ
Ticker Symbol JYB
Full Company Profile

Financial Performance

Financial Statements

News

Urinary disease biotech Jyong Biotech files for a $40 million US IPO

Jyong Biotech, a commercial-stage Taiwanese biotech developing therapies for urinary diseases, filed on Thursday with the SEC to raise up to $40 million in an initial public offering.

9 months ago - Renaissance Capital

Jyong Biotech IPO Registration Document (F-1)

Jyong Biotech has filed to go public with an IPO on the NASDAQ.

9 months ago - SEC